Massmutual Trust Co. FSB ADV Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Massmutual Trust Co. FSB ADV raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.8% in the second quarter, Holdings Channel.com reports. The firm owned 1,150 shares of the medical device company’s stock after purchasing an additional 221 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in DexCom were worth $130,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. International Assets Investment Management LLC bought a new stake in shares of DexCom during the 4th quarter valued at about $1,986,000. Prime Capital Investment Advisors LLC lifted its holdings in DexCom by 150.4% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 7,877 shares of the medical device company’s stock valued at $977,000 after purchasing an additional 4,731 shares in the last quarter. Valley National Advisers Inc. increased its stake in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Eastern Bank raised its position in shares of DexCom by 19.5% during the 4th quarter. Eastern Bank now owns 4,590 shares of the medical device company’s stock valued at $570,000 after purchasing an additional 750 shares during the period. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of DexCom during the 4th quarter valued at $57,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total transaction of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares in the company, valued at $8,055,854.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $119.24, for a total transaction of $77,744.48. Following the completion of the transaction, the executive vice president now owns 67,560 shares in the company, valued at $8,055,854.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,135 shares of company stock valued at $446,797. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on DXCM. Stifel Nicolaus reduced their price objective on shares of DexCom from $132.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. BTIG Research dropped their price target on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Barclays decreased their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. UBS Group reduced their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Finally, Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $111.63.

DexCom Price Performance

DXCM traded up $2.82 during trading on Tuesday, reaching $75.25. The company’s stock had a trading volume of 8,831,194 shares, compared to its average volume of 3,681,164. The company has a market cap of $29.93 billion, a price-to-earnings ratio of 49.32, a PEG ratio of 2.18 and a beta of 1.16. The firm has a fifty day simple moving average of $108.23 and a two-hundred day simple moving average of $121.39. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.34 EPS. As a group, analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.